Top Tweets for #ELAcestrant
We are now enrolling to the #ERADICATE study!
This is a phase Ib/II study of #Elacestrant in combination with #TrastuzumabDeruxtecan (T-DXd) for patients with CDK4/6 inhibitor and endocrine-resistant HR+/HER2-low or HER2-ultralow metastatic #BreastCancer.
To learn more about the #ERADICATE study, call 877-338-7425 orvisit https://t.co/SiyP47T6tI
PI: @KristinaFanucci #MetastaticBreastCancer #MBC #ClinicalTrial #BreastCancerResearch #TDxd
We are now enrolling to the #CAPELA study! This is a new phase II multi-center open-label randomized study of #CAPecitabine in combination with #ELAcestrant versus capecitabine alone in advanced estrogen receptor-positive #BreastCancer.
To learn more about the #CAPELA study call 877-338-7425 or visit https://t.co/QR1kItziLI
PI: @KristinaFanucci #MetastaticBreastCancer #MBC #ClinicalTrial #BreastCancerResearch
📢 We are now enrolling to the #CAPELA study!
This is a new phase II multi-center open-label randomized study of #CAPecitabine in combination with #ELAcestrant versus capecitabine alone in advanced estrogen receptor-positive #BreastCancer.
To learn more about the #CAPELA study call 877-338-7425 or visit https://t.co/QR1kItzQBg
PI: @KristinaFanucci #MetastaticBreastCancer #MBC #ClinicalTrial #BreastCancerResearch
We are now enrolling to the #ERADICATE study!
This is a phase Ib/II study of #Elacestrant in combination with #TrastuzumabDeruxtecan (T-DXd) for patients with CDK4/6 inhibitor and endocrine-resistant HR+/HER2-low or HER2-ultralow metastatic #BreastCancer.
To learn more about the #ERADICATE study, call 877-338-7425 or visit https://t.co/SiyP47T6tI
PI: @KristinaFanucci #MetastaticBreastCancer #MBC #ClinicalTrial #BreastCancerResearch
We are now enrolling to the #CAPELA study! This is a phase II multi-center open-label randomized study of #CAPecitabine in combination with #ELAcestrant versus capecitabine alone in advanced estrogen receptor-positive #BreastCancer.
To learn more about the #CAPELA study call 877-338-7425 or visit https://t.co/QR1kItzQBg
PI: @KristinaFanucci #MetastaticBreastCancer #MBC #ClinicalTrial #BreastCancerResearch
Real-world outcomes data suggest that #elacestrant provides durable disease control for patients with estrogen receptor–positive, HER2-negative, ESR1-mutant metastatic #BreastCancer. https://t.co/NBSmGVrTYI
#SABCS25 Recap #3 | #ELEVATE
Phase II ELEVATE explored oral SERD #elacestrant combinations:
ELA + everolimus: mPFS 8.3 mo
ELA + abemaciclib: mPFS 14.3 mo
Here is my take:
1️⃣ ELA + abemaciclib is striking!
mPFS >14 months regardless of #ESR1 or #PIK3CA status, mostly in 2L pts.
This strongly supports sequential CDK4/6i use, particularly with oral SERDs (assuming no clear CDK4/6 resistance like RB loss)
While consistent with #EMBER3 (imlunestrant + abemaciclib: mPFS 9.4 mo), the ELEVATE results stand out given the more refractory population: ~⅓ had prior fulvestrant and ~25% had primary endocrine resistance — both excluded from EMBER3.
2️⃣ ELA + everolimus showed encouraging signal especially in the ESR1-WT
Benefit was similar in ESR1-mut and ESR1-WT, unlike evERA:
ELA + EVE: ESR1m 8.3 mo, WT 9.0 mo
GIRE + EVE: ESR1m ~10 mo, WT ~6 mo
3️⃣ In ESR1-mut pts, if prior 1L ET + CDK4/6i response ≥12 mo, I would not add everolimus:
EMERALD (ELA): mPFS 8.6 mo
ELEVATE (ELA + EVE): mPFS 8.3 mo
@OncoAlert @OncBrothers @breastfriendspd
📊#SABCS25 Poster Session 5 | PS5-09-15 | #ERADICATE: A phase Ib/II study of #elacestrant plus trastuzumab deruxtecan in patients with CDK4/6 inhibitor and endocrine-resistant HR+/HER2-low or HER2-ultralow #MetastaticBreastCancer. #MBC @drsarahsam @stolaney1 @nlinmd @elmayermd
New 📰 Real-World Outcomes of #Elacestrant in ER+, HER2-, ESR1-mutant #MetastaticBreastCancer.
🔓https://t.co/UHxtpYQxVX
@hoperugo @VKaklamani @hmcarthur @DrWGradishar @DrReshmaMahtani @maryam_lustberg @stolaney1 #MBC #BreastCancer
"LA #TOSCANA CHE CURA IL FUTURO
Un farmaco nato a #Pisa che blocca il tumore al seno.
È di oggi la notizia che #Elacestrant, il primo farmaco orale [...] per il trattamento del #tumore al #seno metastatico, sarà disponibile in Italia entro tre mesi."❤️
(Segue nello screenshot)
![CarlaGommy's tweet photo. "LA #TOSCANA CHE CURA IL FUTURO
Un farmaco nato a #Pisa che blocca il tumore al seno.
È di oggi la notizia che #Elacestrant, il primo farmaco orale [...] per il trattamento del #tumore al #seno metastatico, sarà disponibile in Italia entro tre mesi."❤️
(Segue nello screenshot) https://t.co/Ml0vmyfDnF](https://pbs.twimg.com/media/GttlxVhW0AAT_S4.jpg)
![CarlaGommy's tweet photo. "LA #TOSCANA CHE CURA IL FUTURO
Un farmaco nato a #Pisa che blocca il tumore al seno.
È di oggi la notizia che #Elacestrant, il primo farmaco orale [...] per il trattamento del #tumore al #seno metastatico, sarà disponibile in Italia entro tre mesi."❤️
(Segue nello screenshot) https://t.co/Ml0vmyfDnF](https://pbs.twimg.com/media/Gttla5UXMAAHd31.jpg)
❓Wondering what comes next after administering #elacestrant?
In the 2nd animated video, Prof. Dieci (@vitti10) examines PRO data from #EMERALD, strategies for managing AEs, and treatment options post-2L progression for ER+ mBC patients.
Watch now! 👉 https://t.co/iXKCHtaiWR
Curious about the post-administration landscape of #elacestrant?
In this animated video, Prof. Dieci (@vitti10) explores PRO data from #EMERALD, strategies to manage AEs & #treatment options beyond 2L progression in pts w/ ER+ mBC
Watch here!👉https://t.co/zCGcvFJbG9
#MedEd
👉El @Hospital_FJD lidera un proyecto europeo para optimizar una terapia oral en #CáncerMamaMetastásico #luminal #elacestrant💚🩷💛💙 #MásInvestigaciónParaMásVida®️🔬 https://t.co/om2hZ5tTE4
In 2023, 3 more drugs/indications were approved for #BreastCancer by @FDAOncology @US_FDA:
- #Elacestrant in ESR1 HR+
- #Sacituzumab in endocrine resistant HR+
- #Capivasertib in AKT1/PIK3CA/PTEN mutation HR+
#bcsm #OncTwitter #MedTwitter #oncology @ThanksCancer
3 new drugs/indications were approved by @FDAOncology for Breast Cancer and 2 for Gyn Onc in 2022. Here is a summary!
- #TDXd x 2
- #Olaparib
- #Pembrolizumab
- #Mirvetuximab
#bcsm #gynsm @OncoAlert #breastcancer #MedTwitter #OncEd #MedEd #ovariancancer
SABCS23 Day 1 Highlights by @OncBrothers
@FDAOncology
#Cancer #Capivasertib #CommunityOncology #Dabrafenib #Elacestrant #Oncology #OncoDaily #Oncology #oncologyBrothers #SABCS23 #Selpercatinib #TumorAgnostic
https://t.co/zJZpuqSUej
#SABCS23 | Poster PO2-05-05 | #ELECTRA: An open-label, multicenter, phase 1b/2 study of #elacestrant in combination with #abemaciclib in patients with #BrainMetastasis from ER+, HER2- #BreastCancer | @nlinmd #NuhadIbrahim @evaciruelos @ErikaHamilton9
#SABCS23 | PO2-05-04 Poster | #ELEVATE: A phase 1b/2, open-label, umbrella study evaluating #elacestrant in various combinations in pts with ER+, HER2- locally advanced or #MetastaticBreastCancer. #mBC @stolaney1 @hoperugo @dradityabardia @JavierCortesMD @curijoey @ErikaHamilton9
2. #Elacestrant approved on 1/27/23 based off: EMERAL w/ ESR1 mutation. Elacestrant vs Fulvestrant in 2nd L and beyond.
- mPFS improved w/ Elacestrant
- most Benefit CDK4/6i >12mos
- AE: musculoskeletal pain, nausea, increased cholesterol
https://t.co/TWW19CVZdG
#bcsm
3/6
On the 👠 of @ASCO’s ESR1 rec, we 🗣 #Elacestrant and how it fits in our daily practice for HR+ #breastcancer with @VKaklamani
Full Int:
- https://t.co/Q7GEc99kIb
- https://t.co/OdMGRvntR0
- Also on the “Oncology Brothers” podcast
#bcsm #OncTwitter #MedTwitter @TargetedOnc
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
118.8M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.7M followers